Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.35 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.31 |
| ▸ | ASGR1 | P07306 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22534064 | 1.00 | KDM4E (0.39) | KDM4EALDH1A1RAB9AHTTNCOA1 | |
| SCHEMBL5344420 | 0.83 | KDM4E (0.43) | KDM4EALDH1A1RAB9AHTTNCOA1 | |
| SCHEMBL5413587 | 0.83 | KDM4E (0.43) | KDM4EALDH1A1RAB9AHTTNCOA1 | |
| SCHEMBL3825323 | 0.83 | KDM4E (0.43) | KDM4EALDH1A1RAB9AHTTNCOA1 | |
| SCHEMBL10829859 | 0.79 | CTRB1 (0.33) | KDM4ELMNA | |
| SCHEMBL9648206 | 0.79 | CTRB1 (0.33) | KDM4ELMNA | |
| SCHEMBL1832624 | 0.79 | CTRB1 (0.33) | KDM4ELMNA | |
| SCHEMBL6849200 | 0.77 | KDM4E (0.41) | KDM4ERAB9ALMNA | |
| SCHEMBL7976755 | 0.77 | KDM4E (0.41) | KDM4ERAB9ALMNA | |
| SCHEMBL28819066 | 0.73 | ALDH1A1 (0.42) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220162164-A1 | PROCESSES FOR PREPARING ALPHA-CARBOXAMIDE PYRROLIDINE DERIVATIVES | BIONGEN INC (US) | 2022-05-26 | — | — | US | disclosed |
| US-20220162164-A1 | PROCESSES FOR PREPARING ALPHA-CARBOXAMIDE PYRROLIDINE DERIVATIVES | BIONGEN INC (US) | 2022-05-26 | — | — | US | disclosed |
| CN-114222728-A | Process for preparing alpha-carboxamide pyrrolidine derivatives | 生物基因公司 | 2022-03-22 | — | — | CN | disclosed |
| EP-3953328-A1 | PROCESSES FOR PREPARING ALPHA-CARBOXAMIDE PYRROLIDINE DERIVATIVES | Biogen Inc. (US) | 2022-02-16 | — | — | EP | disclosed |
| WO-2020210486-A1 | PROCESSES FOR PREPARING ALPHA-CARBOXAMIDE PYRROLIDINE DERIVATIVES | BIOGEN INC. (US) | 2020-10-15 | — | — | WO | disclosed |
| JP-2005272327-A | METHOD FOR PRODUCING N-TRIFLUOROACETYLGLUTAMIC ANHYDRIDE | NISSAN CHEM IND LTD | 2005-10-06 | — | — | JP | disclosed |
| US-5430182-A | Substituted acyl derivative; high sweetening potency and stability; for soft drinks | NOFRE CLAUDE (FR) | 1995-07-04 | — | — | US | disclosed |
| US-5374733-A | Stability | NOFRE CLAUDE (FR) | 1994-12-20 | — | — | US | disclosed |
| US-5310908-A | Sweetening agent derived from L-aspartic or L-glutamic acid | NOFRE CLAUDE (FR) | 1994-05-10 | — | — | US | disclosed |
| US-5272272-A | Sweetening agents derived from L-glutamic acid | NOFRE CLAUDE (FR) | 1993-12-21 | — | — | US | disclosed |
| US-5196540-A | SWEETENING AGENT DERIVED FROM L-ASPARTIC OR L-GLUTAMIC ACID | NOFRE CLAUDE (FR) | 1993-03-23 | — | — | US | disclosed |
| EP-0218140-B1 | SUBSTRATES, COMPOSITIONS, ELEMENTS AND METHODS FOR THE DETERMINATION OF GAMMA-GLUTAMYLTRANSFERASE | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1992-01-22 | — | — | EP | disclosed |
| US-5061710-A | Atrial natriuretic factors | SCHERING CORPORATION (US) | 1991-10-29 | — | — | US | disclosed |
| US-4929641-A | DIURETICS, ANGIOTENSIN CONVERTING ENZYMES | SCHERING CORPORATION (US) | 1990-05-29 | — | — | US | disclosed |
| US-4874878-A | CHEMICAL INTERMEDIATES FOR ANTIDEPRESSANTS | ADIR ET CIE (FR) | 1989-10-17 | — | — | US | disclosed |
| US-4851429-A | ANTIDEPRESSANT, TRANQUILIZERS | ADIR ET CIE (FR) | 1989-07-25 | — | — | US | disclosed |
| US-4801609-A | Mercapto-acylamino acid antihypertensives | SCHERING CORPORATION (US) | 1989-01-31 | — | — | US | disclosed |
| US-4751178-A | Substrates, compositions, elements and methods for the determination of gamma-glutamyltransferase | EASTMAN KODAK COMPANY (US) | 1988-06-14 | — | — | US | disclosed |
| EP-0254032-A2 | Neutral metalloendopeptidase inhibitors in the treatment of hypertension | SCHERING CORPORATION (US) | 1988-01-27 | — | — | EP | disclosed |
| EP-0218140-A2 | Substrates, compositions, elements and methods for the determination of gamma-glutamyltransferase | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1987-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220162164-A1 | PROCESSES FOR PREPARING ALPHA-CARBOXAMIDE PYRROLIDINE DERIVATIVES | CPS1, PCCA, SNCA | KDM4E 403/4885ALDH1A1 1155/4885RAB9A 1193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.